Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 5/20 | 0.57 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.56 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.56 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790412 | 0.85 | RAB9A (0.77) | RAB9AEGLN1 | |
| SCHEMBL24898159 | 0.83 | RAB9A (0.66) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5655604 | 0.81 | RAB9A (0.62) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25112299 | 0.81 | RAB9A (0.71) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4097649 | 0.79 | RAB9A (0.61) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2230478 | 0.79 | RAB9A (0.60) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10245110 | 0.78 | RAB9A (0.67) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5500063 | 0.78 | MAPT (0.66) | RAB9ACNR2 | |
| SCHEMBL25474761 | 0.78 | RAB9A (0.58) | RAB9AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13306750 | 0.78 | RAB9A (0.58) | RAB9AHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010024911-A1 | METHODS FOR INCREASING NEUROGENESIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | RAB9A 3637/4885FTO 4088/4885EGLN2 215/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | RAB9A 3695/4885FTO 4102/4885EGLN2 866/4885 |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | RAB9A 3751/4885FTO 4570/4885EGLN2 1043/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | RAB9A 2252/4885FTO 3763/4885EGLN2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.